Antibacterial Efficacy of Two Commercially Available Bacteriophage Formulations, Staphylococcal Bacteriophage and PYO Bacteriophage, Against Methicillin-Resistant Staphylococcus aureus: Prevention and Eradication of Biofilm Formation and Control of a Systemic Infection of Galleria mellonella Larvae
Sessile bacteria growing on surfaces are more resistant to standard antibiotics than their planktonic counterpart. Due to their antimicrobial properties, bacteriophages have re-emerged as a promising approach to treat bacterial biofilm-associated infections. Here, we evaluated the ability of two com...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-02-01
|
Series: | Frontiers in Microbiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fmicb.2020.00110/full |
id |
doaj-38a9e40b0f09415d983af86b061eb78e |
---|---|
record_format |
Article |
spelling |
doaj-38a9e40b0f09415d983af86b061eb78e2020-11-25T03:05:34ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2020-02-011110.3389/fmicb.2020.00110491520Antibacterial Efficacy of Two Commercially Available Bacteriophage Formulations, Staphylococcal Bacteriophage and PYO Bacteriophage, Against Methicillin-Resistant Staphylococcus aureus: Prevention and Eradication of Biofilm Formation and Control of a Systemic Infection of Galleria mellonella LarvaeTamta Tkhilaishvili0Tamta Tkhilaishvili1Lei Wang2Arianna Tavanti3Andrej Trampuz4Andrej Trampuz5Mariagrazia Di Luca6Mariagrazia Di Luca7Mariagrazia Di Luca8Center for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin, Berlin Institute of Health, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, GermanyBerlin-Brandenburg Center for Regenerative Therapies, Charité – Universitätsmedizin Berlin, Berlin, GermanyCenter for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin, Berlin Institute of Health, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, GermanyDepartment of Biology, University of Pisa, Pisa, ItalyCenter for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin, Berlin Institute of Health, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, GermanyBerlin-Brandenburg Center for Regenerative Therapies, Charité – Universitätsmedizin Berlin, Berlin, GermanyCenter for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin, Berlin Institute of Health, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, GermanyBerlin-Brandenburg Center for Regenerative Therapies, Charité – Universitätsmedizin Berlin, Berlin, GermanyDepartment of Biology, University of Pisa, Pisa, ItalySessile bacteria growing on surfaces are more resistant to standard antibiotics than their planktonic counterpart. Due to their antimicrobial properties, bacteriophages have re-emerged as a promising approach to treat bacterial biofilm-associated infections. Here, we evaluated the ability of two commercially available phage formulations, Staphylococcal bacteriophage (containing the monophage Sb-1) and PYO bacteriophage (a polyphage), in preventing and eradicating an in vitro biofilm of methicillin-resistant Staphylococcus aureus (MRSA) by isothermal microcalorimetry and high-resolution confocal laser scanning microscopy (CLSM). Moreover, to assess the potential in vivo efficacy of both phage preparations, a Galleria mellonella model of MRSA systemic infection was used. Microcalorimetry measurement showed that 107 PFU/ml (the highest tested titer) of both phage formulations were able to inhibit planktonic growth in a concentration-dependent manner. However, MRSA biofilm was eradicated only by co-incubation of 5–7 days with the highest phage titers, respectively. In the experiments of biofilm prevention, isothermal microcalorimetry revealed that the heat production was completely abolished in the presence of sub-inhibitory titers (104 PFU/ml) of phages. These data were also confirmed by confocal laser scanning microscopy. Both phage formulations increased the survival of G. mellonella larvae preventing or treating MRSA infection compared to untreated control. In conclusion, tested phage formulations are promising for preventing device colonization and killing biofilm bacteria attached on a surface. Novel strategies for direct coating and release of phages from material should be investigated.https://www.frontiersin.org/article/10.3389/fmicb.2020.00110/fullmethicillin-resistant Staphylococcus aureusbiofilm-associated infectionantimicrobial activitybacteriophagesGalleria mellonellaphage therapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Tamta Tkhilaishvili Tamta Tkhilaishvili Lei Wang Arianna Tavanti Andrej Trampuz Andrej Trampuz Mariagrazia Di Luca Mariagrazia Di Luca Mariagrazia Di Luca |
spellingShingle |
Tamta Tkhilaishvili Tamta Tkhilaishvili Lei Wang Arianna Tavanti Andrej Trampuz Andrej Trampuz Mariagrazia Di Luca Mariagrazia Di Luca Mariagrazia Di Luca Antibacterial Efficacy of Two Commercially Available Bacteriophage Formulations, Staphylococcal Bacteriophage and PYO Bacteriophage, Against Methicillin-Resistant Staphylococcus aureus: Prevention and Eradication of Biofilm Formation and Control of a Systemic Infection of Galleria mellonella Larvae Frontiers in Microbiology methicillin-resistant Staphylococcus aureus biofilm-associated infection antimicrobial activity bacteriophages Galleria mellonella phage therapy |
author_facet |
Tamta Tkhilaishvili Tamta Tkhilaishvili Lei Wang Arianna Tavanti Andrej Trampuz Andrej Trampuz Mariagrazia Di Luca Mariagrazia Di Luca Mariagrazia Di Luca |
author_sort |
Tamta Tkhilaishvili |
title |
Antibacterial Efficacy of Two Commercially Available Bacteriophage Formulations, Staphylococcal Bacteriophage and PYO Bacteriophage, Against Methicillin-Resistant Staphylococcus aureus: Prevention and Eradication of Biofilm Formation and Control of a Systemic Infection of Galleria mellonella Larvae |
title_short |
Antibacterial Efficacy of Two Commercially Available Bacteriophage Formulations, Staphylococcal Bacteriophage and PYO Bacteriophage, Against Methicillin-Resistant Staphylococcus aureus: Prevention and Eradication of Biofilm Formation and Control of a Systemic Infection of Galleria mellonella Larvae |
title_full |
Antibacterial Efficacy of Two Commercially Available Bacteriophage Formulations, Staphylococcal Bacteriophage and PYO Bacteriophage, Against Methicillin-Resistant Staphylococcus aureus: Prevention and Eradication of Biofilm Formation and Control of a Systemic Infection of Galleria mellonella Larvae |
title_fullStr |
Antibacterial Efficacy of Two Commercially Available Bacteriophage Formulations, Staphylococcal Bacteriophage and PYO Bacteriophage, Against Methicillin-Resistant Staphylococcus aureus: Prevention and Eradication of Biofilm Formation and Control of a Systemic Infection of Galleria mellonella Larvae |
title_full_unstemmed |
Antibacterial Efficacy of Two Commercially Available Bacteriophage Formulations, Staphylococcal Bacteriophage and PYO Bacteriophage, Against Methicillin-Resistant Staphylococcus aureus: Prevention and Eradication of Biofilm Formation and Control of a Systemic Infection of Galleria mellonella Larvae |
title_sort |
antibacterial efficacy of two commercially available bacteriophage formulations, staphylococcal bacteriophage and pyo bacteriophage, against methicillin-resistant staphylococcus aureus: prevention and eradication of biofilm formation and control of a systemic infection of galleria mellonella larvae |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Microbiology |
issn |
1664-302X |
publishDate |
2020-02-01 |
description |
Sessile bacteria growing on surfaces are more resistant to standard antibiotics than their planktonic counterpart. Due to their antimicrobial properties, bacteriophages have re-emerged as a promising approach to treat bacterial biofilm-associated infections. Here, we evaluated the ability of two commercially available phage formulations, Staphylococcal bacteriophage (containing the monophage Sb-1) and PYO bacteriophage (a polyphage), in preventing and eradicating an in vitro biofilm of methicillin-resistant Staphylococcus aureus (MRSA) by isothermal microcalorimetry and high-resolution confocal laser scanning microscopy (CLSM). Moreover, to assess the potential in vivo efficacy of both phage preparations, a Galleria mellonella model of MRSA systemic infection was used. Microcalorimetry measurement showed that 107 PFU/ml (the highest tested titer) of both phage formulations were able to inhibit planktonic growth in a concentration-dependent manner. However, MRSA biofilm was eradicated only by co-incubation of 5–7 days with the highest phage titers, respectively. In the experiments of biofilm prevention, isothermal microcalorimetry revealed that the heat production was completely abolished in the presence of sub-inhibitory titers (104 PFU/ml) of phages. These data were also confirmed by confocal laser scanning microscopy. Both phage formulations increased the survival of G. mellonella larvae preventing or treating MRSA infection compared to untreated control. In conclusion, tested phage formulations are promising for preventing device colonization and killing biofilm bacteria attached on a surface. Novel strategies for direct coating and release of phages from material should be investigated. |
topic |
methicillin-resistant Staphylococcus aureus biofilm-associated infection antimicrobial activity bacteriophages Galleria mellonella phage therapy |
url |
https://www.frontiersin.org/article/10.3389/fmicb.2020.00110/full |
work_keys_str_mv |
AT tamtatkhilaishvili antibacterialefficacyoftwocommerciallyavailablebacteriophageformulationsstaphylococcalbacteriophageandpyobacteriophageagainstmethicillinresistantstaphylococcusaureuspreventionanderadicationofbiofilmformationandcontrolofasystemicinfectionofgalleriamellonel AT tamtatkhilaishvili antibacterialefficacyoftwocommerciallyavailablebacteriophageformulationsstaphylococcalbacteriophageandpyobacteriophageagainstmethicillinresistantstaphylococcusaureuspreventionanderadicationofbiofilmformationandcontrolofasystemicinfectionofgalleriamellonel AT leiwang antibacterialefficacyoftwocommerciallyavailablebacteriophageformulationsstaphylococcalbacteriophageandpyobacteriophageagainstmethicillinresistantstaphylococcusaureuspreventionanderadicationofbiofilmformationandcontrolofasystemicinfectionofgalleriamellonel AT ariannatavanti antibacterialefficacyoftwocommerciallyavailablebacteriophageformulationsstaphylococcalbacteriophageandpyobacteriophageagainstmethicillinresistantstaphylococcusaureuspreventionanderadicationofbiofilmformationandcontrolofasystemicinfectionofgalleriamellonel AT andrejtrampuz antibacterialefficacyoftwocommerciallyavailablebacteriophageformulationsstaphylococcalbacteriophageandpyobacteriophageagainstmethicillinresistantstaphylococcusaureuspreventionanderadicationofbiofilmformationandcontrolofasystemicinfectionofgalleriamellonel AT andrejtrampuz antibacterialefficacyoftwocommerciallyavailablebacteriophageformulationsstaphylococcalbacteriophageandpyobacteriophageagainstmethicillinresistantstaphylococcusaureuspreventionanderadicationofbiofilmformationandcontrolofasystemicinfectionofgalleriamellonel AT mariagraziadiluca antibacterialefficacyoftwocommerciallyavailablebacteriophageformulationsstaphylococcalbacteriophageandpyobacteriophageagainstmethicillinresistantstaphylococcusaureuspreventionanderadicationofbiofilmformationandcontrolofasystemicinfectionofgalleriamellonel AT mariagraziadiluca antibacterialefficacyoftwocommerciallyavailablebacteriophageformulationsstaphylococcalbacteriophageandpyobacteriophageagainstmethicillinresistantstaphylococcusaureuspreventionanderadicationofbiofilmformationandcontrolofasystemicinfectionofgalleriamellonel AT mariagraziadiluca antibacterialefficacyoftwocommerciallyavailablebacteriophageformulationsstaphylococcalbacteriophageandpyobacteriophageagainstmethicillinresistantstaphylococcusaureuspreventionanderadicationofbiofilmformationandcontrolofasystemicinfectionofgalleriamellonel |
_version_ |
1724677768306753536 |